<DOC>
	<DOCNO>NCT01214564</DOCNO>
	<brief_summary>This study primarily design investigate whether treatment , daily three consecutive day , PEP005 ( ingenol mebutate ) Gel , 0.05 % safe tolerable patient Seborrhoeic Keratosis non-head location . The secondary endpoint investigate efficacy PEP005 Gel , 0.05 % administer three consecutive day Seborrhoeic Keratosis non-head location .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy PEP005 ( Ingenol Mebutate ) Gel , 0.05 % , Patients With Seborrhoeic Keratosis</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Keratosis , Seborrheic</mesh_term>
	<criteria>Inclusion Criteria 1 . Patient male female least 18 year age . 2 . Female patient must either : Nonchildbearing potential , provide laboratory confirm serum follicle stimulate hormone ( FSH ) level â‰¥ 40mIU/ml confirm clinical history sterility ( e.g. , patient without uterus ) ; Childbearing potential , provide negative urine pregnancy test result prior study treatment , rule pregnancy . 3 . Patient provide informed consent document signing Informed Consent Form ( ICF ) prior studyrelated procedure , include alteration medication preparation study entry . 4 . Patient agree allow photograph select treatment lesion take used part study data package . Exclusion Criteria 1 . Known sensitivity allergy ingredient PEP005 ( ingenol mebutate ) Gel . 2 . Current enrolment participation clinical research study within 30 day entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>PEP005</keyword>
	<keyword>Peplin</keyword>
	<keyword>Seborrhoeic Keratosis</keyword>
</DOC>